The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia (Journal article)

Florentin, M./ Liberopoulos, E. N./ Moutzouri, E./ Rizos, C. V./ Tselepis, A. D./ Elisaf, M. S.

Full metadata record
DC FieldValueLanguage
dc.contributor.authorFlorentin, M.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorMoutzouri, E.en
dc.contributor.authorRizos, C. V.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorElisaf, M. S.en
dc.rightsDefault Licence-
dc.subjectlow density lipoprotein particle sizeen
dc.subjectsmall dense low density lipoproteinen
dc.subjectintima-media thicknessen
dc.subjectc-reactive proteinen
dc.subjectldl subfraction distributionen
dc.subjectmetabolic syndromeen
dc.subjectfamilial hypercholesterolemiaen
dc.subjectstatin therapyen
dc.subjectb metabolismen
dc.titleThe effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemiaen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDoi 10.1185/03007995.2010.546394-
heal.identifier.secondary<Go to ISI>://000287322500021-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.abstractObjective: To compare the effects of simvastatin alone versus simvastatin plus ezetimibe on small dense low-density lipoprotein cholesterol (sdLDL-C) concentration in subjects with primary hypercholesterolemia. Research design and methods: Patients with LDL-C levels above those recommended by the National Cholesterol Education Program Adult Treatment Panel III were randomized to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg as a fixed combination (n=50) daily. LDL particle size (estimated by electrophoresis), sdLDL-C levels, and lipid profile were blindly assessed at baseline and 3 months. Clinical trial registration: NCT00932620. Results: Both simvastatin 40 mg and simvastatin/ezetimibe 10/10 mg decreased total cholesterol (-31% and -36%, respectively), LDL-C (-43% and -49%, respectively), triglycerides (-17% and -19%, respectively), non-high-density lipoprotein cholesterol (non-HDL-C; -40% and -46%, respectively), large LDL-C (-40 and -44%, respectively) and sdLDL-C levels (-42% and -46%, respectively, all p<0.000 vs baseline) and increased LDL particle size (+0.5% and +0.7%, respectively, both p<0.05 vs baseline). The changes in total cholesterol, LDL-C and non-HDL-C were greater in the simvastatin/ezetimibe group (all p<0.05). Changes in triglycerides, large LDL-C, sdLDL-C levels and LDL particle size were similar in the two groups. In multivariate analysis, baseline sdLDL-C and triglyceride levels, but not the choice of treatment, were significantly and independently correlated with the changes in sdLDL-C levels. Conclusion: The combination of simvastatin 10 mg plus ezetimibe 10 mg is similarly effective to simvastatin 40 mg in improving sdLDL-C concentration and LDL particle size in subjects with primary hypercholesterolemia.en
heal.journalNameCurrent Medical Research and Opinionen
heal.journalTypepeer reviewed-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.